Hepatitis B virus induces sorafenib resistance in liver cancer via upregulation of cIAP2 expression.

Shouhua ZhangNuoya LiYanling ShengWen ChenQiangliang MaXin YuJianping LianJunquan ZengYipeng YangJinlong Yan

Published in: Infectious agents and cancer (2021)

cIAP2 is involved in HBV-induced sorafenib resistance in liver cancer and anti-HBV treatments reduce cIAP2 expression and partially restore sorafenib sensibility.

Keyphrases

hepatitis b virus
poor prognosis
liver failure
long non coding rna
binding protein
cell proliferation
signaling pathway
drug induced
endothelial cells
stress induced